0      0

2022 Advanced uroLogic Conference

201 - Bladder Preservation Approaches in Muscle Invasive Bladder Cancer: Where Are We Headed After 40+ Years of Trials?


Apr 2, 2022 7:15am ‐ Apr 2, 2022 8:30am



Credits: None available.

Standard: $30.00
Members: $20.00

Description

Muscle invasive bladder cancer is a lethal disease with substantial quality of life impacts of the ‘standard’ cystectomy approach. Chemoradiation based bladder preservation strategies have demonstrated equitable outcomes in >40 years of studies with ongoing novel integration of immunotherapy promising further improvements. Learn the available data, flexibility of available regimens, and practical steps for ensuring high quality outcomes in practice.

Continuing Education Instructions and Disclosure Information:

Contact hours available until 4/3/24.

Requirements for Successful Completion:

Complete the learning activity in its entirety and complete the online nursing continuing professional development evaluation. You will be able to print your NCPD certificate at any time after you complete the evaluation.

Disclosure of relevant financial relationships with ineligible companies (planners, faculty/speakers, reviewers):

Planning Committee Disclosures:

Christina Hicks, MS, APRN, WHNP-BC discloses that she is a consultant for Urovant Sciences, Ltd.

There are no other Planning Committee disclosures to declare.

Speaker Disclosures:
Neil Desai, MD, MHS discloses that he is a consultant for Boston Scientific and receives clinical trial funding for prostate cancer (not related to presentation content).

There are no other speaker disclosures to declare.

Commercial Support:
No commercial support declared.

Accreditation Statement:
The Society of Urologic Nurses and Associates (SUNA) is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

SUNA accreditation is reciprocal in the states and specialty organizations that recognize the ANCC-COA accreditation process. SUNA is an approved provider of continuing nursing education by the California Board of Registered Nursing, Provider Number CEP 5556. Accreditation and approved provider status of NCPD does not imply ANCC-COA approval or endorsement of any product, advertising, or educational content. SUNA urges all participants to be aware of the requirements for re-licensure in the states in which they hold a license.

Learning Outcome:
After completing this education activity, the learner will be able to implement a standardized discussion of bladder preservation therapy and workflow in treatment of bladder cancer as an equitable alternative to cystectomy in selected patients.

Speaker(s):

  • Neil Desai, MD, MHS, Associate Professor, University of Texas Southwestern Medical Center

Credits Available


Bladder Preservation Approaches in Muscle Invasive Bladder Cancer: Where Are We Headed After 40+ Years of Trials?

You must be logged in and own this session in order to post comments.